Gaucher Disease

  • Hiroyuki IdaEmail author


A 7-month-old infant was admitted to the hospital because of afebrile convulsion. The patient was born with a normal pregnancy at full term. The delivery was uncomplicated. He developed normally until 3 months of age. However, he manifested stridor and poor feeding at 4 months old and exhibited retroflexion of the neck and strabismus. Feeding problems and difficulty in handling secretion appeared at 6 months old. He manifested tonic-clonic convulsion without fever. Since convulsion continued for more than 30 min, he was transferred to the emergency room.


Gaucher disease Genotype/phenotype correlation Enzyme replacement therapy Pharmacological chaperone therapy Substrate reduction therapy 


  1. Amaral O, Lacerda L, Marcao A, Pinto E, Tamagnini G, Miranda MCS (1999) Homozygosity for two mild glucocerebrosidase mutations of probable Iberian origin. Clin Genet 56:100–102CrossRefGoogle Scholar
  2. Andersson H, Kaplan P, Kacena K, Yee J (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122:1182–1190CrossRefGoogle Scholar
  3. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC (2015) Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilized on enzyme replacement therapy: a phase 3, randomized, open-label, non-inferiority trial. Lancet 385:2355–2362CrossRefGoogle Scholar
  4. Horowitz M, Tzuri G, Eyal N, Berebi A, Kolodony EH, Brady RO, Barton NW, Abrahamov A, Zimran A (1993) Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am J Hum Genet 53:921–930PubMedPubMedCentralGoogle Scholar
  5. Ida H, Iwasawa K, Kawame H, Rennert OM, Maekawa K, Eto Y (1995) Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. Hum Genet 95:717–720CrossRefGoogle Scholar
  6. Ida H, Rennert OM, Ito T, Maekawa K, Eto Y (1998) Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells, Mol Dis 24:73–81CrossRefGoogle Scholar
  7. Narita A, Higaki K, Maegaki Y, Ohno K, Suzuki Y (2016) Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Translat Neurol 3:200–215CrossRefGoogle Scholar
  8. Parenti G (2009) Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 1:268–279CrossRefGoogle Scholar
  9. Ringden O, Groth CG, Erikson A, Granqvist S, Mansson JE, Sparrelid E (1995) Ten years’s experience of bone marrow transplantation for Gaucher disease. Transplantation 59:864–870CrossRefGoogle Scholar
  10. Sibille A, Eng CM, Kim SJ, Pastores G, Grabowski GA (1993) Phenotype/genotype correlations in Gaucher disease type 1: clinical and therapeutic implications. Am J Hum Genet 52:1094–1101PubMedPubMedCentralGoogle Scholar
  11. Tajima A, Yokoi T, Ariga M, Ito T, Kaneshiro E, Eto Y, Ida H (2009) Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol Genet Metab 97:272–277CrossRefGoogle Scholar
  12. Weinreb NJ, Charrow J, Andersson HC, Laplan P, Kolodony EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A (2002) Effectiveness of ERT in 1028 patients with type 1 Gaucher disease after 2 to 5 years treatment. Am J Med 113:112–119CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of PediatricsThe Jikei University School of MedicineTokyoJapan

Personalised recommendations